CAPR
Capricor Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$6.38Close
$366.0MMarket cap
$3.85 – $35.3452-week range
Nov 9, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 25 · weaker than 75% of stocks over 12 months
- Far from its high 82% below its 52-week high
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
82%
1wk
up 7.6%
price change
1mo
down 32.6%
price change
12-month return
up 3%
market up 11% ·
its own down 19%
F-score
—
— Not assessed
Altman Z
3.14
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.2×
price / book
Earnings yield
down 138.3%
EBIT / enterprise value
Cheaper than
31%
of the market · expensive
Revenue growth
down 100%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 47%
return on equity
Free cash margin
—
-$72.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
9.7%
$0.62 a day · 2×ATR $5.14
RS
25 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.46
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 1 of 8
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 25.9% over the year, from 46m to 57m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 100.0% over the year.
Last reported
Aug 13, 2026
Last shock
Jul 27, 2026-64% in one session12.7× volumeon an SEC filing-9% since
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $310,250 | $244,898 | $2.6M | $25.2M | $22.3M | $0 |
| Operating income | -$13.7M | -$20.9M | -$29.7M | -$24.1M | -$42.6M | -$108.1M |
| Net income | -$13.7M | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105.0M |
| Net margin | -4402% | -8176% | -1137% | -89% | -182% | — |
| Earnings per share | -$0.88 | -$0.87 | -$1.18 | -$0.83 | -$1.15 | -$2.26 |
| Free cash flow | -$10.6M | -$18.0M | $2.9M | -$26.9M | -$41.2M | -$72.7M |
| Free cash margin | -3417% | -7352% | 114% | -107% | -185% | — |
| Cash | $32.7M | $34.9M | $9.6M | $14.7M | $11.3M | $287.8M |
| Long-term debt | $71,471 | $0 | — | — | — | — |
| Shareholders' equity | $28.2M | $31.4M | $11.8M | $22.6M | $145.5M | $305.8M |
| Shares outstanding | 20.58m | 24.19m | 25.24m | 31.15m | 45.58m | 57.37m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 14, 2026 | Quarterly ↗ | Jun 30, 2026 | 45d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 17, 2026 | Annual ↗ | Dec 31, 2025 | 76d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 26, 2025 | Annual ↗ | Dec 31, 2024 | 85d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 11, 2024 | Annual ↗ | Dec 31, 2023 | 71d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 24, 2026 | Other events ↗ |
| Aug 13, 2026 | Results ↗ |
| Jul 30, 2026 | Other events ↗ |
| Jul 29, 2026 | Other events ↗ |
| Jul 14, 2026 | Material agreement · New obligation ↗ |
| Jun 26, 2026 | Other events ↗ |
| Jun 8, 2026 | Shareholder vote ↗ |
| May 12, 2026 | Results ↗ |
| May 7, 2026 | Regulation FD · Other events ↗ |
| Mar 12, 2026 | Results ↗ |
| Mar 10, 2026 | Regulation FD · Other events ↗ |
| Dec 5, 2025 | Regulation FD · Other events ↗ |